GSK submits its first application for daprodustat in Japan; Two drugmakers part with $15M to avoid opioid trial
→ Just as Hal Barron planned, GSK $GSK has submitted its first regulatory application for its oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), daprodustat, in Japan for patients with renal anemia due to chronic kidney disease (CKD). The application is based on positive Phase III data conducted in Japan on anemic patients across the spectrum of CKD from stages 3-5 — which included patients on and not on dialysis, regardless of prior anemia treatment with erythropoiesis-stimulating agents (ESAs). If approved, daprodustat will be exclusively distributed in Japan by Kyowa Kirin Co.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.